Aisin Zhiyao is an innovative drug developer. Based on its groundbreaking computational biology platform, it conducts in-depth analysis of multi-omics data from patients, finds new mechanisms and drug targets that drive disease progression, and develops innovative drugs. . Through deep learning (Deep Learning) and other AI technologies, the patient’s multi-omics big data (including single-cell and spatial omics) are systematically analyzed, and the key cell types and intracellular and extracellular signaling pathways leading to disease progression are discovered, and the selection of potential solutions to major clinical problems New targets in demand for the development of first-in-class drugs. Recently, Aisin Zhiyao completed an angel round of financing of tens of millions of yuan, led by Qiming Venture Capital, and joined by Sany Innovation Investment and Huatong Capital. The raised funds will be used for the construction of the core technology platform and the advancement of the R&D pipeline.
This article is reproduced from: https://www.itjuzi.com/investevent/13551170
This site is for inclusion only, and the copyright belongs to the original author.